IMPACT OF T315I MUTATION ON THE OUTCOME OF IMATINIB-RESISTANT CML IN EGYPTIAN PATIENTS

  • Assistant Professor, Hematology Department, Medical Research Institute, Alexandria University. Egypt.
  • Assistant Consultant, Hematology Department, Medical Research Institute, Alexandria University. Egypt.
  • Professor, Hematology Department, Medical Research Institute, Alexandria University. Egypt.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: BCR-ABL T315I BCRT315I mutation is one of the most frequently identified mutations in Imatinib-resistant chronic myelogenous leukemia (CML) patients. However, its clinical impact remains controversial. Objectives: to assess the clinical characteristics and outcome of T315I mutation in 79 Egyptian patients with CML after failure of Imatinib therapy. Results: T315I mutation was present in 14 (18%) patients. The level of resistance was heterogeneous. Forty nine patients were in chronic phase, 7 in accelerated phase, and 23 in blast crisis. Imatinib dose escalation in 2 resistant patients with T315+ showed transient good response. Responses were also observed in 3 out of 8 patients who were shifted to 2nd generation Tyrosine Kinase Inhibitor (TKI) after Imatinib resistance. There was no difference in patient characteristics and survival between T315I+ and T315I- patients. Conclusion: the survival of T315I+ patients remains mainly dependent on the disease phase and the response duration. The difference in the disease outcome from most of previously reported studies may be related to mutation heterogeneity and to different ethnicity of patient population. Evaluation of chromosomal abnormalities other than Ph1, and additional mutation at T315I identification is needed to know if there are other mechanisms of resistance.

  1. Jabbour E, Kantarjian H. Introduction: chronic myelogenous leukemia (CML). Semin Hematol 2007; 44:S1-3.
  2. Deininger M, Goldman , Lydon N, Melo J. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691?3698.
  3. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCRABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2(2):117-25.
  4. Quint?s-Cardama A,Kantarjian HM,?Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer control 2009; 16(2): 122-3.
  5. Luzzatto L, Melo JV. Acquired resistance to imatinib mesylate: Selection for pre- existing mutant cells. Blood 2002 ; 99(9):3472-5.
  6. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8(11):1018-29.
  7. Branford S,Rudzki Z,?Walsh S,?Parkinson I,?Grigg A,?Szer J,?et al. Detection of?BCR-ABL?mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis, Blood?2003; 102:276-283.
  8. Soverini S,Martinelli G,?Rosti G,?Bassi S,?Amabile M,?Poerio A,?et al. ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 18: 4100?4109.
  9. Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O?Brien S, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008;112: 53-55.
  10. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122(6):872-884.
  11. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1985: 457-481.
  12. Wongboonma W, Thanegnoppakyhum W, Auewarakul CU. A single- tube allele specific ?polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients. J Hematol 2011; 4: 7- 11.
  13. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O?Brien S, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006; 20(10):1767-1773.
  14. Nicolini FE, Corm S, Le Q-H, Sorel N, Hayette S, Bories D, et al. Mutation status and clinical outcome of 89 imatinib mesylate resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi-LMC GROUP). Leukemia 2006; 20(6):1061-1066.
  15. Norozi F, Mohammadi-asl J, Vosoughi T, Jalali Far MA, Malehi AS, Saki N. Incidence of T315I mutation in BCR/ABL-positive CML and ALL patients. Front Biol 2016, 11(5): 404?411.
  16. Kagita S, Uppalapati S, Jiwatani S, Linga V G, Gundeti S, Nagesh N, Digumarti R. Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India. Tumour Biol 2014; 35(7): 7187?7193.
  17. Soverinia S, Branford S, Nicolini FE, Talpazf M, Deiningerg MWN, Martinellia G, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res 2014; 38:10? 20.
  18. Meggyesi N,Kozma A,?Halm G,?Nahajevszky S,?B?tai A,?Fekete S,?et al. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients. Acta Haematol 2012; 127: 34?42.
  19. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI 571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014?1018.
  20. Kreuzer KA, Le Coutre P, Landt O, Na IK, Schwarz M, Schultheis K et al. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol 2003; 82: 284?289.
  21. Willis S, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, et al. High sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106(6):2128-37.
  22. Hochhaus A, Kreil S, Corbin AS, La Ros?e P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance toimatinib (STI571) therapy. Leukemia 2002; 16: 2190?2196.
  23. Al-Ali HK,Heinrich MC,?Lange T,?Krahl R,?Mueller M,?M?ller C,?et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004; 5: 55?60.
  24. Hochhaus A. Dynamics of mutated clones in chronic myeloid leukemia patients. Haematologica 2009;78-82.
  25. Bixby D, Talpaz, M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program 2009: 461?476
  26. Jabbour E, Kantarjian H, Cortes J. Chronic myeloid leukemia. Emerg Cancer Ther 2011b; 2: 239?258.
  27. Zhang WW, Cortes JE, Yao H, Zhang L, Reddy N, Jabbour E, et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 2009; 27: 3642?3649.
  28. Ng K, Hillmer A, Chuah C, Juan W, Ko T, Teo A, BAuthor%et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012; 18(4): 521?528.
  29. de Lavallade H, Khorashad JS, Davis HP, Milojkovic D, Kaeda JS, Goldman JM, et al. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood. 2007; 110(7):2779-80.
  30. Hanfstein B, Muller MC, Kreil S, Ernst T, Schenk T, Lorentz C, BAuthor%et al. Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica. 2011; 96(3):360-6.
  31. Rudzki J, Wolf D. Dose Escalation of Imatinib in Chronic-phase Chronic Myeloid Leukemia Patients. Is it Still Reasonable? Expert Rev Hematol?2011; 4(2):153-159.
  32. Laneuville P, Dilea C, Yin OQ, Woodman RC, Mestan J, Manley PW. Comparative?in vitrocellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.?J Clin Oncol 2010;?28(11), e169?e171.
  33. Yamamoto M, Kurosu T, Kakihana K, Mizuchi D, Miura O. The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase Biochem Biosphys Res Commun 2004; 319:1272-5.
  34. Ernst T, Hoffmann J, Erben P, Hanfstein B, Leitner A, Hehlmann R, et al. ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2008; 93(9):1389?1393
  35. Nicolini FE, Hayette S, Corm S, Bachy E, Bories D, Tulliez M, et al. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica 2007; 92(09):1238-1241.
  36. Hiwase DK, Yeung DT, White DL. Optimizing the Selection of Kinase Inhibitors for Chronic Myeloid Leukemia PatientsExpert Rev Hematol.?2011;4(3):285-299.
  37. Talpaz M,?BAuthor%D&cauthor=true&cauthor_uid=16775234"Shah NP,?Kantarjian H,?Donato N,?Nicoll J,?BAuthor%D&cauthor=true&cauthor_uid=16775234"Paquette R,?BAuthor%et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med.2006 Jun 15; 354(24):2531-2541.
  38. Kantarjian H,?BAuthor%D&cauthor=true&cauthor_uid=16775235"Giles F,?Wunderle L,?Bhalla K,?BAuthor%D&cauthor=true&cauthor_uid=16775235"O'Brien S,?Wassmann B,?BAuthor%et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006; 354(24):2542-2551.
  39. Nicolini FE, Mauro MJ, Martinelli G, Kim D-W, Soverini S, M?ller MC, et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABLT315I mutation. Blood 2009 ; 114: 5271-5278.
  40. Griswold IJ, MacPartlin M, Bumm T, Goss VL, O?Hare T, Lee KA, BAuthor%et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol. 2006;26:6082-6093.
  41. Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, M?ller MC, Hochhaus A, et al. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica 2013; 98(10): 1510-1516.
  42. O?Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, BAuthor%et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500?4505.
  43. Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, et al. High sensitivity detection of BCR-ABL kinase domain mutations in imatinib-na?ve patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 2005;106(6):2128-37.

[Mohamed Amr El-Menoufy, Amel Aly El Naggar and Laila El-Sayed Ziada. (2017); IMPACT OF T315I MUTATION ON THE OUTCOME OF IMATINIB-RESISTANT CML IN EGYPTIAN PATIENTS Int. J. of Adv. Res. 5 (May). 2165-2175] (ISSN 2320-5407). www.journalijar.com

Mohamed Amr El-Menoufy
Assistant Professor of Hematology

DOI:

Article DOI: 10.21474/IJAR01/4365      
DOI URL: https://dx.doi.org/10.21474/IJAR01/4365

Download Full Paper

Download PDF No. of Downloads: 20 | No. of Views: 106